Condition
Acute Cellular Graft Rejection
Total Trials
6
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Completed2
Withdrawn1
Active Not Recruiting1
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT03719339Active Not Recruiting
VIRTUUS Children's Study
NCT05499637Phase 2RecruitingPrimary
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
NCT03304626Phase 2CompletedPrimary
Budesonide for Liver Transplant Immune Suppression
NCT04105803Unknown
Cardiac Mitochondrial Function After Heart Transplantation
NCT03393793Completed
HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
NCT03315052Phase 4WithdrawnPrimary
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
Showing all 6 trials